Saturday, May 31, 2008
Q; 65 year old female admitted to ICU 9 days ago with small bowel obstruction. Pt. is now stable and actually is about to get transferred out of unit. Patient suddenly start complaining of choking sensation with two hands on neck. Monitor shows oxygen desaturation. Patient intubated emergently. No laryngeal or vocal edema seen on laryngoscope but vocal cord paralysis noted.
A; Nasogastric tube syndrome
Nasogastric tube syndrome was described about 25 years ago by Sofferman and coll. It is a life-threatening complication of an indwelling (more than a week) nasogastric tube. The syndrome may present as complete vocal cord abductor paralysis. The syndrome is thought to result from perforation of the NG tube-induced esophageal ulcer and infection of the posterior cricoid region (postcricoid chondritis) with subsequent dysfunction of vocal cord abduction. Unilateral paralysis of cord is also described. Treatment is protection of airway, removal of NG tube and antibiotics. Some advocates antireflux therapy too. Another variant is described with no esophageal ulcer but possibly because of ischemia of the laryngeal abductor muscle secondary to physical compression of the postcricoid blood vessels by NG tube .
References: Please click to get abstract
1. The nasogastric tube syndrome: two case reports and review of the literature. Head Neck. 2001 Jan;23(1):59-63.
2. A variant form of nasogastric tube syndrome. Intern Med. 2005 Dec;44(12):1286-90.
3. Case Report - Nasogastric Tube Syndrome: The Unilateral Variant - Medical Principles and Practice Vol. 12, No. 1, 2003
4. Sofferman, R.A. and Hubbell, R.N., "Laryngeal Complications of Nasogastric Tubes," ANNALS OTOLOGY, RHINOLOGY, AND LARYNGOLOGY, 90:465-468, 1981.
Friday, May 30, 2008
Friday May 30, 2008
An update on VAP (Ventilator Associated Pneumonia)
There have been several studies recently published in the journal of critical care medicine on Ventilator Associated Pneumonia (VAP). The VAP Guidelines Committee and the Canadian Critical Care Trials Group has made evidence based recommendations for the prevention, diagnosis and treatment of VAP.
- For VAP prevention, the group recommend that the orotracheal route of intubation should be used for intubation
- a new ventilator circuit for each patient
- circuit changes if the circuit becomes soiled or damaged, but no scheduled changes
- change of heat and moisture exchangers every 5 to 7 days or as clinically indicated
- the use of a closed endotracheal suctioning system changed for each patient and as clinically indicated
- subglottic secretion drainage in patients expected to be mechanically ventilated for more than 72 hours
- head of bed elevation to 45 degrees (when impossible, as near to 45 degrees as possible should be considered)
- the use of rotating beds;
- oral antiseptic rinses.
The group do not recommend:
- use of bacterial filters;
- the use of iseganan,
make no recommendations regarding:
- the use of a systematic search for sinusitis;
- type of airway humidification;
- timing of tracheostomy;
- prone positioning;
- aerosolized antibiotics;
- intranasal mupirocin;
- topical and/or intravenous antibiotics.
For the diagnosis and treatment of VAP, the group recommends that
- endotracheal aspirates with nonquantitative cultures be used as the initial diagnostic strategy.
- When there is a suspicion of VAP, they recommend empiric antimicrobial therapy (in contrast to delayed or culture directed therapy) and appropriate single agent antimicrobial therapy for each potential pathogen as empiric therapy for VAP.
- Choice of antibiotics should be based on patient factors and local resistance patterns.
- They recommend that an antibiotic discontinuation strategy be used in patients who are treated of suspected VAP.
- For patients who receive adequate initial antibiotic therapy, they recommend 8 days of antibiotic therapy.
- The group does not recommend nebulized endotracheal tobramycin or intratracheal instillation of tobramycin for the treatment of VAP.
Clickhere to get VAP prevention getting started kit from IHI
Reference: Click to article
1. Comprehensive evidence-based clinical practice guidelines for ventilator-associated pneumonia: prevention. - J Crit Care. 2008 Mar;23(1):126-37.
2. Comprehensive evidence-based clinical practice guidelines for ventilator-associated pneumonia: diagnosis and treatment. - J Crit Care. 2008 Mar;23(1):138-47
Thursday, May 29, 2008
Wellens syndrome (LAD coronary T-wave syndrome)
The EKG changes of Wellens syndrome can be easily recognized, many ED and ICU physicians are not aware of this. Wellens syndrome is associated with critical proximal left anterior descending artery lesion. These patients are at very high risk and immediate catheterization is recommended. The EKG pattern of the T-wave changes present in the mid-precordial leads characterized by either
- deeply symmetric inverted T-waves (Type 1 Wellen) or
- biphasic T-waves (Type 2 Wellen)
See ppt. presentation 12 Lead Basics Wellens Syndrome
These are mostly read as non specific T wave abnormalities as mostly these EKG changes appear during pain free period of Angina.
The cardiac enzymes are generally negative. The excercise stress test can provocate acute infarction. Most of these patients will develop anterior wall MI within a few weeks. Cardiac catheterization is indicated in these patients.
Read here case report with discussion (pdf) on Wellens Syndrome
(Ayman A. Elmenyar, MBBch, Msc., HEART VIEWS VOL. 1 NO. 10 DECEMBER 2000- FEBRUARY 2001: 408-410)
See here very good power point presentation including EKGs
(slide 1 to 30 is Wellens Syndome) - Francis Mencl MD, MS, FACEP
Reference: Click to article
1. Ayman A. Elmenyar: Electrocardiographic Diagnosis Of Critical Left Coronary Arterial System Stenosis: The Internet Journal of Cardiology. 2004; Volume 2, Number 2.
2. Electrocardiographic manifestations of Wellens' syndrome. Am J Emerg Med. 2002 Nov;20(7):638-43.
Wednesday, May 28, 2008
Role of Micro-nutrient in Cardiomyopathy
A relatively small but important study to know !
A recent report by Matthew Harinstein described 11 patients with idiopathic dialted cardiomyopathy who had evidence of myocardial "viability" (dysfunctional but noncontractile myocardium that has the potential for improvement in function) as assessed by cardiac magnetic resonance imaging, low-dose dobutamine echocardiography, or nuclear imaging.
These patients were treated with standard therapies including [beta]-blockers, angiotensin-converting enzyme inhibitors, digoxin, and potassium and non-potassium-sparing diuretics. The majority of patients received micronutrient supplementation with coenzyme Q10, vitamin B1, and amino acids, which target the pathways of cardiac metabolism and may aid in the restoration of cardiac function.
The average ejection fraction at presentation was 17% +/- 9% which improved to 59% +/- 5%. All patients improved to New York Heart Association functional class I with available therapy.
This case series demonstrates that normalization of cardiac function is possible with standard therapy and the importance of assessing myocardial viability in all patients with heart failure and reduced ejection fraction. Given the unique metabolic needs of the failing heart, the role of micronutrients in combination with standard therapy warrants further investigation.
Reference: Click to get abstract
Harinstein M, Berliner J, Shah S, Taegtmeyer H, Gheorghiade M. Normalization of Ejection Fraction and Resolution of Symptoms in Chronic Severe Heart Failure is Possible With Modern Medical Therapy: Clinical Observations in 11 Patients. American Journal of Therapeutics. 15(3):206-213, May/June 2008.
Tuesday, May 27, 2008
7 "Ps" of intubation
In response to our pearl from yesterday on 5 'P' Philosophy, we received following email. We are presenting it as a pearl today
I read with interest you post today with 5 'Ps' for Critical Care procedure. Actually, its true for any procedure anwhere. I always teach my residents and fellows, 7 "Ps" of intubation.
- Pre-oxygenate the patient
- Prepare the equipments
- Put down (sedate) the patient
- Paralyse the patient
- Place the tube
- Placement confirmation (via auscultation, EZcap or CXR)
- Pen down (document) the procedure
Monday, May 26, 2008
Q; What is the five (5) "P" Philosophy before doing any Critical Care procedure?
A: Proper Preparation Prevents Poor Performance
Sunday, May 25, 2008
Q; 84 year old female admitted with syncope and frequent episode of hypotension. Following EKG is obtained. What is your diagnosis (Hint - 3 marked circles) and what intervention is required in view of hemodynamic instability?
A: This is 'trifasicular' block
- Complete Right Bundle Branch Block (red)
- Left Anterior Hemiblock (Green)
- Long PR interval - first degree AV block (blue)
In view of hemodynamic instability, a temporary or may be a permanent pacemaker is needed.
Saturday, May 24, 2008
Brain Death Site
Important handy site related to info. needed for brain death examination. Site is solely dedicated to provide information about brain death.
All information is scientific and based on the American Acadamy of Neurology Guidelines.
Most featured aspects we found are
- page dedicated to
Friday, May 23, 2008
Q; How much intavenous albumin should be given to patient while removing ascitic fluid via paracentesis?
A; Per 2004 guidelines published in Hepatology 2004 Mar;39(3):841-56, for management of adult patients with ascites due to cirrhosis by Practice Guidelines Committee, American Association for the Study of Liver Diseases (AASLD),
"Post-paracentesis albumin infusion may not be necessary for a single paracentesis of less than 4 to 5 L. For large-volume paracenteses, an albumin infusion of 8 to 10 g per liter of fluid removed can be considered".
Thursday, May 22, 2008
Plavix (Clopidogrel) associated TTP
An important reminder regarding Plavix.
Clopidogrel (Plavix) is used commonly in patients with cerebrovascular and coronary disease as an antiplatelet drug. Now there are substantial number of cases reported in literature of thrombotic thrombocytopenic purpura (TTP) associated with use of Clopidogrel (Plavix).
Clopidogrel-associated TTP often occurs within 2 weeks of drug initiation and has a high mortality if not treated promptly.
Key is prompt diagnosis as the survival rate for clopidogrel-associated TTP is almost 100% if therapeutic plasma exchange performed within 3 days of onset of TTP (100% vs 27.3%).
References: Click to get abstract if available
1. Clopidogrel-Associated TTP - Stroke. 2004;35:533
2. Clopidogrel and thrombotic thrombocytopenic purpura: No clear case for causality - CLEVELAND CLINIC JOURNAL OF MEDICINE , VOLUME 70 • NUMBER 5, MAY 2003 -pdf file
3. Thrombotic thrombocytopenic purpura associated with clopidogrel administration: case report and brief review. Am J Med Sci 2001; 322:170–172.
4. Plasmapheresis improves survival in drug-induced thrombotic thrombocytopenic purpura: systematic review of published case reports [abstract]. Blood 2001; 98(Suppl 1):60b.
5. Thrombotic thrombocytopenic purpura occurring after exposure to clopidogrel [abstract]. Blood 1999; 94(Suppl 1):78b.
6. Clopidogrel-associated TTP [abstract]. Transfusion 1999; 39(Suppl):56S.
7. Clopidogrel and thrombotic thrombocytopenic purpura. N Engl J Med 2000; 343:1193–1194.
Wednesday, May 21, 2008
Troponin I Elevation in patients without Acute Coronary Syndromes !
Q; How many patients may have Cardiac Troponin I elevation without Acute Coronary Syndromes ?
A; Upto 35% !!
In a recent paper, just published in Am J Cardiol 1, 883 consecutive hospitalized patients were studied with increased cardiac troponin I levels. The discharge diagnosis was reclassified and troponin increase attributed to ACS or another process. Patients were followed for a median of 30 months.
Results: 311 patients were classified as having a non-ACS–related troponin increase (35.2%). An alternative explanation for troponin increase was found in 99% of these patients. Troponin level had poor accuracy in discriminating patients with and without ACS.
Of the 311 patients without ACS,
- 89 (28%) were diagnosed as having sepsis,
- 49 (16%) had acute left heart failure,
- 41 (13%) were after coronary artery bypass graft,
- 31 (10%) had atrial or ventricular arrhythmia,
- 23 (7%) were after cardiopulmonary resuscitation,
- 21 (7%) had a cerebrovascular event,
- 11 (4%) had myocarditis,
- 11 (4%) had acute bleeding,
- 10 (3%) had chest contusion,
- 6 (2%) had pulmonary embolism.
- 19 patients (6%) had another diagnosis such as diabetic ketoacidosis, carbon monoxide intoxication, pancreatitis, hypoxemia, hypercarbia, lymphoma, and electrocution.
Mean serum troponin level for
- patients without ACS were significantly lower (15.3 +/- 15.9 ng/ml)
- the values of patients with STEMI (32.5 +/- 18.1 ng/ml)
- NSTEMI (20.4 +/- 18.4 ng/ml)
- The highest troponin level in the non-ACS group was found in 10 patients diagnosed as having myocarditis (27.7 +/- 21.5 ng/ml)
Coronary angiography was frequently unhelpful in excluding a non-ACS–related troponin increase because 77% of patients in the non-ACS group had significant flow-limiting coronary artery disease.
But patients with non-ACS–related troponin increase had significantly higher in-hospital and long-term mortalities compared with patients with ACS.
Cardiac Troponin I Elevation in Hospitalized Patients Without Acute Coronary Syndromes - Am J Cardiol 2008;101:1384–1388, 15 May 2008
Tuesday, May 20, 2008
Tuesday May 20, 2008
Acute Liver Failure
Q; The chances of survival with medical management in acute liver failure is 26%. How much difference liver transplant can make?
A; It goes upto 90% !!
Watch video lecture
Acute Liver Failure: The Critical Team Approach *
Dr. Lorenzo Rossaro, Chief of Gastroenterology and Hepatology and Head of the Liver Transplant Program at University of California Davis Medical Center.
*Total time: 42 minutes. Please click on above link. You need Real Player to watch the lecture
Monday, May 19, 2008
Hydrocortisone in septic shock - controversy continues
Controversy over use of Hydrocortisone in septic shock has been hot particularly after recent publication and criticism of CORTICUS trial. Just few days ago, we posted a concise commentary on this issue from Dr. Jean-Louis Vincent (here). One very recent study (from Annane group) now looked into relationship between cardiovascular autonomic modulation and adrenal function during sepsis.
Patients and Method: Cardiovascular variability was assessed by spectral analysis of heart rate and diastolic blood pressure signals, which included computation of normalized low (LFnu) and high frequency (HFnu) components.
In study phase 1, the spectral analysis of heart rate and diastolic blood pressure was obtained in five septic shock and six healthy volunteers before and 60 min after a single intravenous bolus of 50 mg of hydrocortisone.
In study phase 2, the spectral analysis of heart rate and diastolic blood pressure was obtained in 47 consecutive patients with septic shock immediately before a 250 μg adrenocarticotropic hormone (ACTH) stimulation test and before initiation of corticosteroids. Spectral components were compared between patients with adrenal insufficiency and those with presumed normal adrenal function. Adrenal insufficiency was defined as a basal cortisol of less than 15 μg/dl or a maximal cortisol increment after 250 μg of ACTH of less than 9 μg/dl.
Study phase 3 focused on 23 consecutive patients with septic shock and adrenal insufficiency. Spectral components were obtained immediately before and at day 3 after initiation of 50 mg every 6 hrs of hydrocortisone and 50 μg daily of fludrocortisone, or their respective placebos in a double blind manner.
- As compared to healthy volunteers, patients had decreased LFnu-HR and LFnu-DBP and, after hydrocortisone, they had a greater increase in LFnu-DBP (p = .01)
- As compared to patients with normal adrenal function, those with adrenal failure had decreased LFnu-HR and LFnu-DBP
- In patients with adrenal failure, as compared to placebos, hydrocortisone plus fludrocortisone increased significantly LFnu-DBP (p = .02) and low frequency/high volume ratio (p = .009)
Conclusion: In septic shock, the loss in cardiovascular variability is more marked in patients with adrenal insufficiency and is partly restored by exogenous administration of corticosteroids.
Reference: click to get abstract
Hydrocortisone effects on cardiovascular variability in septic shock: A spectral analysis approach - Critical Care Medicine. 36(5):1481-1486, May 2008.
Sunday, May 18, 2008
Case: 58 year old male with history of "CHF" presents to ER with shortness of breath. On exam patient appear to have classic signs of 'exacerbation of CHF'. Patient also complain of nausea, vomiting, diarrhea and abdominal pain. Also, patient sees everything green, double and blurred ! Labs are not back yet but following EKG is obtained. With above history, what is your suspicion ?
Answer: Digoxin Toxicity
The 3 major hallmarks on EKG of Digoxin toxicity
- accelerated junctional rhythm, also called "regularized Atrial Fibrillation"
- ST segment sagging (This finding is not indicative of toxicity unless other signs present)
- a shortened QT interval
First rule is - Comparison with previous EKGs.
Many times, its hard to find any specific EKG sign. Digoxin toxicity may cause any dysrhythmia including paroxysmal atrial tachycardia with 2:1 block, accelerated junctional rhythm, or even torsade de pointes. Premature ventricular contractions (PVCs) are very common. Bigeminy or trigeminy can be seen frequently. Sinus bradycardia, other bradyarrhythmias, First- and second-degree AV block, complete AV dissociation, and third-degree heart block are very common too.
Cardiac arrest - Ventricular tachycardia,asystole, ventricular fibrillation - is hard to rescue and usually fatal.
Saturday, May 17, 2008
Diastolic Blood Pressure: A Reliable Early Predictor of Survival in Human Septic Shock !
Very interesting article published this month 1. A must read !!
Background: Emphasis in therapy of human septic shock is shifting towards reliable end points and predictors of survival. Rationale is to study whether the evolution of cardiovascular reactivity in view of the administered doses of norepinephrine is an early predictor of inhospital survival and to determine the optimal threshold of norepinephrine therapy and its consequences on renal function.
Methods: Observational study of a prospective cohort of patients in septic shock, hospitalized in ICU least 24 hours before requiring norepinephrine.
Excluded were patients requiring less than 72 hours of continuous norepinephrine (16 patients) or who received corticosteroids.
Hemodynamic parameters (heart rate, blood pressure, urinary output, and temperature) were continuously monitored.
Results: Of 68 patients, 45 survived ICU stay of 24 (12–36) days, hospital stay of 36 (27– 66) days], and 23 died 5 (3–10) days after septic shock onset and norepinephrine treatment.
Multivariate analysis revealed four independent positive predictive factors of short-term (10 days) outcome:
- Simplified Acute Physiology Score (SAPS) II less than 50
- on day 3 Logistic Organ Dysfunction System (LODS) score less than 6
- norepinephrine concentration less than 0.5 g/kg/min
- diastolic arterial pressure >50 mm Hg, but not systolic arterial pressure
Conclusions: Septic shock survival increases when dose of 0.5 g/kg/min of norepinephrine continuously improves vascular tone within the first 48 hours, or when diastolic arterial pressure (>50 mm Hg) is restored. Norepinephrine has beneficial effects on renal function. Predictive value of LODS score on day 3 is demonstrated, while SAPS II is confirmed as the only reliable predictive factor in first 24 hours.
Pearl contributed by
Anthony Halat, M.D.
ICU Physician, Medical ICU,
The Methodist Hospital,
Texas Medical Center, Houston, TX
Reference: click to get abstract
Diastolic Arterial Blood Pressure: A Reliable Early Predictor of Survival in Human Septic Shock. - Journal of Trauma-Injury Infection & Critical Care. 64(5):1188-1195, May 2008.
Friday, May 16, 2008
Q: 52 year old male, who recently travelled, having charity work at rural africa, presented with shortness of breath. Following CXR was obtained. On examination, patient noticed to have 'painless' ucerated lesions over skin.
With travel history, widened mediastinum and ulcerated cutaneous ulcer. What is your biggest concern?
Anthrax is primarily a disease of livestock, such as sheep, cattle, or goats, and most cases occur in developing countries. But lately it found fame as a potential agent of bio-terrorism.
Progressive widened mediastinum is one hallmark of anthrax infection. Inhalational anthrax presents as hemorrhagic mediastinitis, not pneumonia, which may be associated with bloody pleural effusions.
Cutaneous anthrax (skin manifestation) is most common and begins as a pruritic papule that enlarges in 24-48 hours to form an ulcer surrounded by edematous halo. The cutaneous anthrax ulcer is usually pruritic but not painful.
Penicillin, Doxycycline or any Quinolone is the treatment.
See concise ppt presentation on Anthrax here (from Suzanne R. White, M.D., Departments of Emergency Medicine & Pediatrics, Wayne State University, Detroit Medical Center, Michigan)
Thursday, May 15, 2008
Studies after studies have suggested that quality of care in hospital ICUs is strongly influenced by whether intensivists are providing care and the staff organization in the ICU. Mortality rates are significantly lower in hospitals with ICUs managed exclusively by board-certified intensivists. Research has shown that in ICUs where intensivists manage or co-manage all patients versus low intensity there is a 30% reduction in hospital mortality and a 40% reduction in ICU mortality.
If you need to talk to hospital administration ! and for more information on Leapfrog’s ICU Physician Staffing requirements, click on below links and keep in file (pdf documents).
Leapfrog’s ICU Physician Staffing requirements (updated April '08)
Leapfrog’s ICU Physician Staffing Bibliography (33 references - updated Feb. 2008)
Wednesday, May 14, 2008
BNP to predict weaning from ventilator?
Very interesting observation !
Introduction: Despite the use of spontaneous breathing trial (SBT), predicting weaning success remains a major clinical challenge. Because cardiovascular dysfunction could be a major underlying mechanism of weaning failure, role of the levels of B-type natriuretic peptide (BNP), a marker for cardiovascular function, was evaluated in patients who passed a 2 hour SBT.
Design, Setting, and Patients: It was a 3 step study, First: 52 patients recovering from acute respiratory failure were enrolled as the testing group to determine the predictive value of BNP. Second: The predictive value of BNP was validated in a second independent cohort of 49 patients. Third: Both groups of patients were combined to conduct the final analysis.
Measurements and Results:
In the testing group of 52 patients, 41 passed SBT and were extubated. Of these patients, 33 patients (80%) were extubated successfully (extubation success) while eight patients (20%) were reintubated within 48 hrs (extubation failure). There were no differences in the baseline BNP levels, but the extubation failure group had significantly greater increases in BNP at the end of SBT than the extubation success groups
An increase of BNP less than 20% during SBT had the best combination of sensitivity, specificity, positive and negative predictive values, and diagnostic accuracy for predicting extubation success (91%, 88%, 97%, 70%, and 91%).
Combining BNP with SBT as extubation criteria increased the extubation success rate to 95% from 78% using SBT alone (p = .035).
Conclusion: Measuring the percentage change in the BNP level during a SBT may help improve the predictive value of SBT on weaning outcome.
Reference: click to get abstract
Changes in B-type natriuretic peptide improve weaning outcome predicted by spontaneous breathing trial - Critical Care Medicine. 36(5):1421-1426, May 2008.
Tuesday, May 13, 2008
Adrenal insufficiency in prolonged critical illness
Interesting work from Taiwan !
Introduction: Adrenal insufficiency is frequently found in critically ill patients and affects their prognosis. But little is known about how the adrenal function changes during prolonged critical illness. This study was conducted to investigate the dynamic changes of cortisol levels in patients with critical illness who do not improve after treatment.
Methods: This observational cohort study was performed in the intensive care units of a university hospital. Acutely ill patients with initial cortisol level above 34mug/dL but without improvement after treatment, and who had follow-up cortisol levels during their critical illness, were studied. All clinical information and outcomes were recorded.
Results: 53 patients (with initial cortisol level above 34mug/dL) were included.
- 10 patients had follow-up cortisol levels remained more than 34mug/dL,
- 32 patients between 34 and 15mug/dL, and
- 15 patients less than 15mug/dL
Outcomes did not differ significantly among the three groups with different second cortisol levels.
In Cox regression analysis, patients who survived to hospital discharge with second cortisol levels less than 15mug/dL had a longer hospital length of stay (p = 0.004).
Conclusion: The majority of acutely ill patients who remained in critical condition had decreased serum cortisol levels. Lower follow-up cortisol levels might lead to worse clinical outcomes. Repeated testing for adrenal function is suggested for patients with prolonged critical illness.
Reference: click to get abstract
Adrenal insufficiency in prolonged critical illness: Critical Care 2008, 12:R65
Monday, May 12, 2008
On Zosyn's (Piperacillin/tazobactam) dose in nosocomial and ventilator-associated pneumonia
Does Piperacillin/tazobactam (Zosyn) reaches adequate alveolar concentration (as needed in nosocomial and ventilator-associated pneumonia) at any dose of continuous infusion? Recent study by Emmanuel helped to address this issue.
Patients: 40 patients with microbiologically documented ventilator-associated pneumonia (VAP).
Interventions: Patients were randomized to receive piperacillin/tazobactam daily continuous infusions of
- 12/1.5 g/day or
- 16/2 g/day after a loading dose of 4/0.5 g
Conclusions: A target piperacillin serum concentration of at least 35-40 mg/L is probably required to provide alveolar concentrations exceeding the susceptibility breakpoint for Gram-negative bacteria (16 mg/L) during ventilator-associated pneumonia.
In patients with no/mild renal failure, a continuous daily dose of piperacillin/tazobactam 16/2 g/day allows reaching this target concentration, which might be not observed with 12/1.5 g/day.
In patients with moderate/advanced renal failure, both dosages achieve serum concentrations far above the 35-40 mg/L threshold, suggesting that in that case, therapeutic drug monitoring should be performed in order to adjust the daily dose.
Editors' comment: Zosyn is a frequent antibiotic used for Nosocomial and VAP(Ventilator associated Pneumonia) in USA but mostly in divided doses, instead of continuous infusion (as this study was done in France). This study translates into conclusion that patients with no renal insufficiency requires higher dose of Zosyn to treat Nosocomial and VAP (around 4.5 q 6 hours). But patients with renal insufficiency needs lower dose and drug monitoring is recommended.
reference: click to get abstract
Boselli E, Brelith D, Rimmele T, Guillaume C, Xuereb F, Saux MC, et al. Alveolar concentrations of piperacillin/tazobactam administered in continuous infusion to patients with ventilator-associated pneumonia. Critical Care Medicine. 36(5):1500-1506, May 2008.
Sunday, May 11, 2008
Q: According to landmark expert panel conference of 1991/1992, under the auspices of the American College of Chest Physicians and the Society of Critical Care Medicine, what is the widely accepted definition of SIRS (Systemic inflammatory response syndrome) ?
A: SIRS is defined as 2 or more of the following variables:
- Fever of more than 38°C ( 100.4°F) or less than 36°C ( 96.8°F)
- Heart rate of more than 90 beats per minute
- Respiratory rate of more than 20 breaths per minute or a PaCO2 level of less than 32 mm Hg
- Abnormal white blood cell count (>12,000/µL or <4,000/µl>>10% bands)
Bone RC, Balk RA, Cerra FB, et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Chest. 1992;101:1656-1662
Saturday, May 10, 2008
Comprehensive site for anyone interested to learn and to have resource link available in cardiac anaesthesia and cardiopulmonary bypass.
(Page of Australian & New Zealand College of Perfusionists)
Friday, May 9, 2008
Bedside tip - Changing cordis to tripple lumen
This is a regular practice to change cordis (large bore or rapid infuser catheter) to (small bore) central line "over wire", once need for cordis itself is over (like removal of pulmonary artery catheter or need of rapid fluid infusion).
One frequent issue is inability to advance wire in cordis. As cordis is large bore, its 'hub' (see picture below) tends to bend at skin or inside sucutaneous tissue, which prevents advancement of wire. Trick is to retract the cordis about 1-2 cm out of skin, make it straight and advance wire.
Proceed further with usual practice of changing catheters over wire.
Previous related pearls:
Peres Nomogram to calculate required length of central line
Bedside tip - central line removal
Suture at central venous catheter site - a risk ?
Appropriate length of guide wire to advance
Thursday, May 8, 2008
Extracorporeal membrane oxygenation (ECMO) refers to the technique of providing both cardiac and respiratory support oxygen to patients by draining blood from the venous system and oxygenating it outside of the body. ECMO uses cardio-pulmonary bypass technology to temporarily provide gas exchange to patients with severe, but potentially reversible, respiratory failure. ECMO is a standard practice in neonatal and pediatric ICUs to support pulmonary failure but remained a very last resort in adult ICUs due to the high technical demands, cost, and risk of bleeding (requires anticoagulation). The major reason ECMO remained unused in adult ICUs is a negative study done about 29 years ago. The National Institutes of Health trial of ECMO in severe acute respiratory failure in 1979 showed mortality in excess of 90% .
ECMO could be a bridge till definite therapy is sought or till healing occurs. Technically, VV or VA (veno-veno or veno-arterial) ECMO can provide sufficient oxygenation for several weeks.
One recent trial called CESAR (Conventional Ventilation or ECMO for Severe Adult Respiratory Failure) showed increase survival among adult patients with severe but potentially reversible respiratory failure compared with conventional ventilatory support.
Data from CESAR trial showed that ECMO may increase the rate of survival without severe disability 6 months after randomization and may be cost-effective compared with conventional ventilatory support.
The conventional treatment group was treated with standard clinical practice, with a low-volume ventilation strategy.
The primary outcome measure was death or severe disability 6 months after randomization and included deaths before hospital discharge if occurring after 6 months.
Severe disability was defined as being both "confined to bed" and "unable to wash or dress oneself."
Patients: A total of 180 patients from 68 centers were randomly assigned to receive
- conventional ventilation (n = 90)
- ECMO (n = 90)
Of the 90 patients assigned to receive ECMO, 22 did not receive ECMO, most often because they improved without it.
A significant number of patients had failure of more than 3 organs in both groups (28 in the ECMO group and 27 in the conventional group).
- Of the patients randomly assigned to receive ECMO, 57 of 90 met the primary endpoint of survival or absence of severe disability at 6 months compared with 41 of 87 evaluable patients in the conventional ventilation group (survival benefit 63% vs 47%).
Conclusion: The benefit of ECMO was seen regardless of several factors including hospital of trial entry, age, presence of hypoxia, duration of high-pressure ventilation, primary diagnosis at trial entry, and number of organs failed.
Initial data presented by Giles J. Peek, MD, FRCS, from the University of Leicester, Glenfield, United Kingdom, at the Society of Critical Care Medicine 37th Critical Care Congress 2008, Hawaii.
Pre-report details can be read
Wednesday, May 7, 2008
Q: How nebivolol (Bystolic), the newly approved beta-blocker, is different from previously approved 18 other beta-blockers?
A: Nebivolol is said to be the 19th beta blocker approved for US market. Nebivolol (Bystolic), is approved by FDA for the treatment of hypertension. The drug is a selective beta 1 blocker but has the added pharmacological properties of producing vasodilation and reducing total peripheral resistance brought about by modulation of nitric-oxide release, rather any receptor blockade.
Coreg (Carvedilol) is another new generation b-blocker which does vasoldilation, but via alpha receptor blocakade.
Because of vasodilatory properties Nebivolol and Coreg have also shown benefit (vs placebo) in heart failure. Unlike Coreg, Nebivolol is not approved for the treatment of heart failure (yet).
Previous related pearls: Regarding Coreg
Tuesday, May 6, 2008
DNR Song - funny but so true !
Monday, May 5, 2008
Q: What is the drug of choice to control cocaine induced seizures?
A: Diazepam and lorazepam.
Also, barbiturates, may be effective in controlling seizures because they may act synergistically with the benzodiazepines.
Important pearl to remember is: Phenytoin may not be effective against cocaine-induced seizures.
Sunday, May 4, 2008
Q: What is the ratio of alpha and beta blockade in Labetalol?
A: As an anti-hypertensive, Labetalol has both alpha-blockade and beta-blockade activity. The ratio of alpha to beta blockade activity is
1:3 when used Orally
1:7 when used intravenously
1. I.V. LABETALOL AND CORONARY ARTERY SURGERY, MOREL et al. Br. J. Anaesth..1984; 56: 664-665
2. Comparative study of esmolol and labetalol to attenuate haemodynamic responses after electroconvulsive therapy - Kathmandu University Medical Journal (2007), Vol. 5, No. 3, Issue 19, 318-323, pdf file
Saturday, May 3, 2008
Steroids in sepsis controversy - what 'Guru' thinks !
Here is a very well rounded commentary on steroids in sepsis from internationally famed Critical Care master Dr. Jean-Louis Vincent. We are just posting important points from commentary due to space constrain. You can read full text with references by clicking at link below:
"............Forty years ago, high-dose steroids were used in the belief that, because sepsis is an inflammatory response, the anti-inflammatory properties of steroids could be useful. Initial studies were encouraging, with Schumer demonstrating that treatment with one or two doses of intravenous dexamethasone (3 mg/kg) or methylprednisolone (30 mg/kg) was associated with reduced mortality compared with saline treatment in patients with septic shock. Two large, double-blind, randomized controlled trials later failed to confirm these findings, however, and two meta-analyses in the mid 1990s concluded that steroids were ineffective or indeed were potentially harmful in sepsis.
Then, in the late 1990s, several studies were published suggesting a role for much smaller, so-called stress, doses of steroids in reducing vasopressor requirements in patients with septic shock. These results led to a study by Annane and colleagues in which patients with relative adrenal insufficiency – as assessed by nonresponse to a corticotropin test – who were treated with hydrocortisone (50 mg intravenously every 6 hours) and fludrocortisone (50 μg orally daily) for 7 days had a reduced mortality compared with nonresponders treated with placebo. Despite concerns regarding the lack of statistical significance in overall mortality rates at 28 days, the results from this study led to steroids being recommended in the treatment of patients with septic shock. Steroid use was also incorporated into the so-called sepsis bundles, with the recommendation that all patients with septic shock should receive low-dose corticosteroids within 24 hours of diagnosis.
Doubts remained, however, and a large, international, multicenter study was conducted to confirm the results of the earlier study. The Corticus – Corticosteroid Therapy of Septic Shock – study, which included close to 500 patients, recently showed that hydrocortisone did not improve survival or reversal of shock in patients with septic shock, either overall or in patients who did not respond to a corticotropin test. The results from the Corticus study were somewhat disappointing, and, in the accompanying editorial, Dr Finfer suggested the need for a further study to explore the effects of steroids in septic shock in a much larger population. With no signal from the Corticus study, however, merely increasing the size of the study is unlikely to show mortality differences.
Importantly, apart from the differences in effects on outcome, there were other notable differences between the Corticus study and Annane and colleagues' study, including the larger number of postoperative patients, the more common abdominal source of the sepsis, and, in particular, the lower severity of illness in the Corticus study. This latter factor is particularly important and can be explained by the fact that many patients with severe septic shock were treated with steroids in accordance with guidelines current at the time of the study, and hence were excluded from enrollment – so the included population, by definition, consisted of less severely ill patients. As a result of this lower severity of illness, the mortality rate in the Corticus study was about one-half that of Annane and colleagues' study. It is therefore still possible that steroids may decrease mortality in very ill patients, just not in those with moderately severe shock.
Similar observations were made with activated protein C, another adjunct therapy for sepsis, which was shown to reduce mortality in very ill patients but not in those patients with a lower risk of death. I believe we do need another trial of steroids in sepsis, but specifically in patients with severe septic shock rather than just in a larger general population of septic shock patients.
...................Perhaps the time has come to take a step back and reflect on past efforts so that future clinical trials will be conducted in an optimal manner to limit the pendulum effect and to provide results that stand up to scrutiny and can be immediately introduced into clinical practice to the benefit of our patients."
Reference: Steroids in sepsis: another swing of the pendulum in our clinical trials, Jean-Louis Vincent, Department of Intensive Care, Université libre de Bruxelles, Erasme Hospital, Brussels, Belgium, Critical Care 2008, 12:141
Friday, May 2, 2008
Digoxin recall !!
A class I recall is being issued on all Digitek (digoxin) tablets, which may contain twice the approved level of digoxin.
Digitek is a registered trademark of Actavis Totowa (formerly Amide Pharmaceutical, Inc.) for their digoxin tablets. The drug is distributed by Mylan Pharmaceuticals Inc., under a “Bertek” label and by UDL Laboratories, Inc. under a “UDL” label.
See FDA press release here
Previous related pearls on "Dig."
Treating Digoxin toxicity 1
Treating Digoxin Toxicity 2
What Dig. level makes you happy?
Adenosine and Digoxin !
Thursday, May 1, 2008
Conivaptan's (Vaprisol) drug interactions
Q: Conivaptan (Vaprisol), a Vasopressin Antagonist, which is indicated for the management of euvolemic hyponatremia - can increase the concentration of following drugs if use concomittently? (choose one)
A) Amlodipine (Norvasc)
B) Simvastatin (Zocor)
C) Digoxin (Lanoxin)
D) Midazolam (Versed)
E) All of the above
Answer is E: All of the above
Administration of oral conivaptan 40 mg twice daily with amlodipine besylate (Norvasc) resulted in a two-fold increase in the AUC concentration and increased half-life of amlodipine.
The combined use of IV conivaptan and midazolam should be avoided, because the AUC concentration of midazolam may be increased by two-fold to three-fold when these agents are used together.
The coadministration of conivaptan and HMG-CoA reductase inhibitors (statins) such as simvastatin (Zocor) should also be avoided because the AUC concentration of the statin is increased by three-fold.
Digoxin when taken with oral conivaptan, results in a 30% reduction in clearance of digoxin.
Read nice review on Conivaptan
(reference: P&T • March 2007 • Vol. 32 No. 3, Page 140)